---
title: "Theravance生物制藥 (TBPH.US) — 財務報表"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/TBPH.US/norm.md"
symbol: "TBPH.US"
name: "Theravance生物制藥"
parent: "https://longbridge.com/zh-HK/quote/TBPH.US.md"
datetime: "2026-05-22T01:40:51.178Z"
locales:
  - [en](https://longbridge.com/en/quote/TBPH.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TBPH.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TBPH.US/norm.md)
---

# Theravance生物制藥 (TBPH.US) — 財務報表

## 損益表 (USD)

| 指標 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -0.0962 | 1.15 | 0.0700 | 1.08 | -0.2732 |
| ROE | -6.72% | 92.22% | 6.32% | 112.24% | -31.81% |
| 營業收入 | 17.70M | 45.89M | 19.99M | 26.20M | 15.39M |
| 凈利潤 | -4.93M | 61.02M | 3.62M | 54.84M | -13.58M |
| 營業利潤 | -5.85M | 20.01M | -6.46M | -2.73M | -14.43M |
| 毛利率 | 67.07% | 83.96% | 59.42% | 59.95% | 25.58% |
| 凈利率 | -27.87% | 132.98% | 18.08% | 209.33% | -88.24% |
| 利潤含金量 | -7.98% | -330.00% | - | -1.31% | -33.54% |

## 資產負債表 (USD)

| 指標 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 資產與負債 | 472.31M | 485.57M | 415.46M | 426.04M | 343.58M |
| 權益乘數 | 1.63 | 1.64 | 1.79 | 1.89 | 2.07 |
| 每股凈資產 | 5.64 | 5.81 | 4.59 | 4.46 | 3.32 |
| 資產周轉率 | 0.2691 | 0.2559 | 0.2082 | 0.1959 | 0.1826 |
| 現金及短投 | 394.67M | 315.36M | 329.68M | 338.80M | 130.85M |
| 存貨與應收 | - | - | - | - | - |
| 長期投資 | 28.54M | 30.27M | 31.71M | 33.13M | 34.46M |
| 凈債務 | -354.16M | -283.78M | -288.11M | -292.35M | -82.70M |

## 現金流量表 (USD)

| 指標 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 經營現金流 | 73.28M | -6.06M | -6.51M | 208.07M | 43.04M |
| 投資現金流 | 52.59M | 588000.00 | -100.25M | -36.26M | 30.63M |
| 融資現金流 | -5.58M | -1.49M | -400000.00 | -503000.00 | -854000.00 |
| 自由現金流 | 76.09M | -58.74M | -12.82M | 19.12M | 49.86M |
| 現金流充裕率 | - | -75800.00% | - | 611982.35% | - |
| 舉債與償債 | - | - | - | - | - |
| 資本支出 | - | -8000.00 | 0.0000 | -34000.00 | - |